Literature DB >> 23580644

Transgenic mouse α- and β-cardiac myosins containing the R403Q mutation show isoform-dependent transient kinetic differences.

Susan Lowey1, Vera Bretton, James Gulick, Jeffrey Robbins, Kathleen M Trybus.   

Abstract

Familial hypertrophic cardiomyopathy (FHC) is a major cause of sudden cardiac death in young athletes. The discovery in 1990 that a point mutation at residue 403 (R403Q) in the β-myosin heavy chain (MHC) caused a severe form of FHC was the first of many demonstrations linking FHC to mutations in muscle proteins. A mouse model for FHC has been widely used to study the mechanochemical properties of mutated cardiac myosin, but mouse hearts express α-MHC, whereas the ventricles of larger mammals express predominantly β-MHC. To address the role of the isoform backbone on function, we generated a transgenic mouse in which the endogenous α-MHC was partially replaced with transgenically encoded β-MHC or α-MHC. A His6 tag was cloned at the N terminus, along with R403Q, to facilitate isolation of myosin subfragment 1 (S1). Stopped flow kinetics were used to measure the equilibrium constants and rates of nucleotide binding and release for the mouse S1 isoforms bound to actin. For the wild-type isoforms, we found that the affinity of MgADP for α-S1 (100 μM) is ~ 4-fold weaker than for β-S1 (25 μM). Correspondingly, the MgADP release rate for α-S1 (350 s(-1)) is ~3-fold greater than for β-S1 (120 s(-1)). Introducing the R403Q mutation caused only a minor reduction in kinetics for β-S1, but R403Q in α-S1 caused the ADP release rate to increase by 20% (430 s(-1)). These transient kinetic studies on mouse cardiac myosins provide strong evidence that the functional impact of an FHC mutation on myosin depends on the isoform backbone.

Entities:  

Keywords:  Cardiac Myosin Isoforms; Cardiomyopathy; Cardiovascular Disease; Familial Hypertrophic Cardiomyopathy; Kinetics; Myosin; Myosin Heavy Chain Mutations; Transgenic Mice; Transient Kinetics

Mesh:

Substances:

Year:  2013        PMID: 23580644      PMCID: PMC3663502          DOI: 10.1074/jbc.M113.450668

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Differing ADP release rates from myosin heavy chain isoforms define the shortening velocity of skeletal muscle fibers.

Authors:  S Weiss; R Rossi; M A Pellegrino; R Bottinelli; M A Geeves
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

2.  Analysis of myosin heavy chain functionality in the heart.

Authors:  Maike Krenz; Atsushi Sanbe; Florence Bouyer-Dalloz; James Gulick; Raisa Klevitsky; Timothy E Hewett; Hanna E Osinska; John N Lorenz; Christine Brosseau; Andrea Federico; Norman R Alpert; David M Warshaw; M Benjamin Perryman; Steve M Helmke; Jeffrey Robbins
Journal:  J Biol Chem       Date:  2003-03-06       Impact factor: 5.157

3.  R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level.

Authors:  K A Palmiter; M J Tyska; J R Haeberle; N R Alpert; L Fananapazir; D M Warshaw
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

4.  Kinetic differences in cardiac myosins with identical loop 1 sequences.

Authors:  J S Pereira; D Pavlov; M Nili; M Greaser; E Homsher; R L Moss
Journal:  J Biol Chem       Date:  2000-11-13       Impact factor: 5.157

5.  Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy.

Authors:  M J Tyska; E Hayes; M Giewat; C E Seidman; J G Seidman; D M Warshaw
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

6.  Molecular mechanics of mouse cardiac myosin isoforms.

Authors:  Norman R Alpert; Christine Brosseau; Andrea Federico; Maike Krenz; Jeffrey Robbins; David M Warshaw
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-10       Impact factor: 4.733

Review 7.  Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy.

Authors:  Susan Lowey
Journal:  Trends Cardiovasc Med       Date:  2002-11       Impact factor: 6.677

8.  Cardiac myosin isoforms exhibit differential rates of MgADP release and MgATP binding detected by myocardial viscoelasticity.

Authors:  Yuan Wang; Bertrand C W Tanner; Andrew T Lombardo; Sarah M Tremble; David W Maughan; Peter Vanburen; Martin M Lewinter; Jeffrey Robbins; Bradley M Palmer
Journal:  J Mol Cell Cardiol       Date:  2012-10-30       Impact factor: 5.000

9.  Orthologous myosin isoforms and scaling of shortening velocity with body size in mouse, rat, rabbit and human muscles.

Authors:  M A Pellegrino; M Canepari; R Rossi; G D'Antona; C Reggiani; R Bottinelli
Journal:  J Physiol       Date:  2003-02-01       Impact factor: 5.182

10.  Mutations in the motor domain modulate myosin activity and myofibril organization.

Authors:  Qun Wang; Carole L Moncman; Donald A Winkelmann
Journal:  J Cell Sci       Date:  2003-09-02       Impact factor: 5.285

View more
  20 in total

1.  Absence of the Drosophila jump muscle actin Act79B is compensated by up-regulation of Act88F.

Authors:  Tracy E Dohn; Richard M Cripps
Journal:  Dev Dyn       Date:  2018-02-06       Impact factor: 3.780

2.  Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function.

Authors:  Ruth F Sommese; Jongmin Sung; Suman Nag; Shirley Sutton; John C Deacon; Elizabeth Choe; Leslie A Leinwand; Kathleen Ruppel; James A Spudich
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

3.  Phosphorylation of myosin regulatory light chain has minimal effect on kinetics and distribution of orientations of cross bridges of rabbit skeletal muscle.

Authors:  Divya Duggal; Janhavi Nagwekar; Ryan Rich; Krishna Midde; Rafal Fudala; Ignacy Gryczynski; Julian Borejdo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-11-27       Impact factor: 3.619

4.  Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy.

Authors:  Sarah R Clippinger; Paige E Cloonan; Lina Greenberg; Melanie Ernst; W Tom Stump; Michael J Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-19       Impact factor: 11.205

Review 5.  Functional Assays to Screen and Dissect Genomic Hits: Doubling Down on the National Investment in Genomic Research.

Authors:  Kiran Musunuru; Daniel Bernstein; F Sessions Cole; Mustafa K Khokha; Frank S Lee; Shin Lin; Thomas V McDonald; Ivan P Moskowitz; Thomas Quertermous; Vijay G Sankaran; David A Schwartz; Edwin K Silverman; Xiaobo Zhou; Ahmed A K Hasan; Xiao-Zhong James Luo
Journal:  Circ Genom Precis Med       Date:  2018-04

6.  Effect of a myosin regulatory light chain mutation K104E on actin-myosin interactions.

Authors:  D Duggal; J Nagwekar; R Rich; W Huang; K Midde; R Fudala; H Das; I Gryczynski; D Szczesna-Cordary; J Borejdo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-13       Impact factor: 4.733

7.  Disease modelling and drug discovery for hypertrophic cardiomyopathy using pluripotent stem cells: how far have we come?

Authors:  Chi Keung Lam; Joseph C Wu
Journal:  Eur Heart J       Date:  2018-11-14       Impact factor: 29.983

Review 8.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

9.  Increased myocardial short-range forces in a rodent model of diabetes reflect elevated content of β myosin heavy chain.

Authors:  Charles S Chung; Mihail I Mitov; Leigh Ann Callahan; Kenneth S Campbell
Journal:  Arch Biochem Biophys       Date:  2013-09-04       Impact factor: 4.013

10.  Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.

Authors:  Susan Lowey; Vera Bretton; Peteranne B Joel; Kathleen M Trybus; James Gulick; Jeffrey Robbins; Albert Kalganov; Anabelle S Cornachione; Dilson E Rassier
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.